Episode summary
Kimberly-Clark to Buy Tylenol Maker Kenvue for $40 Billion | Bloomberg Intelligence
Bloomberg Intelligence
· · Hosts: Paul Sweeney, Scarlet Fu · Guests: Diana Gomes, Mandeep Singh, Matthew Palazola
Summary
Kimberly-Clark’s $40 billion cash-and-stock deal for Kenvue drew skepticism because Kenvue’s growth has been weak, legal risk around Tylenol remains elevated, and the combined company will be hard to integrate while Kimberly-Clark is still simplifying its own portfolio. One analyst said the price implies an enterprise value multiple around 14 times 2025 earnings, below prior consumer health transactions, but that discount reflects both Kenvue’s operating problems and the liability overhang. The analyst also said the most plausible value creation is through cost and revenue synergies, though that makes the deal more complex and increases execution risk.
On AI infrastructure, an analyst said Amazon’s $38 billion deal with OpenAI should be viewed as part of a much larger race for compute, not as a standalone headline. OpenAI is pursuing massive capacity additions, with prior deals cited at $300 billion with Oracle and $250 billion with Microsoft. The analyst argued the economics are clearer in infrastructure than in applications, because cloud and data-center spending can be tied to revenue, while the payoff from AI software products is still hazy.
Berkshire Hathaway’s record cash pile and strong operating earnings raised the familiar question of what Warren Buffett’s successor will do with the money. One analyst said the company has underperformed since Buffett’s succession announcement and has not bought back stock, suggesting management may still view the shares as fully valued. The analyst expects capital returns will matter more under Greg Abel, but said Berkshire’s sheer size makes it hard to move the needle with acquisitions.
Key takeaways
- A Bloomberg Intelligence analyst said Kimberly-Clark’s Kenvue deal looks more like a turnaround bet than a simple brand acquisition because Kenvue still faces weak growth and legal risk.
- The analyst said the roughly 14 times EV-to-earnings valuation appears below prior consumer health deals, which helps explain why the market questioned the price.
- On OpenAI, the analyst argued the real monetization case is infrastructure, not applications, and said Amazon’s $38 billion deal could add about $5 billion of revenue over time.
- The analyst said OpenAI’s funding power is supported by a $500 billion valuation and rapid ARR growth, making a public listing likely if revenue scales as expected.
- For Berkshire, the analyst said the company has not repurchased stock since Buffett’s succession announcement, implying management may still see limited value at current levels.
Notable quotes
“it shows that Ken View really has a lot of work to do to turn around the business”
“we are talking about revenue synergies as well as cost synergies and this will be quite a complex um new company”
“the entire gigawatt capacity of all the hyperscalers combined is around that ballpark 30 gawatt”
“the path right now is through AI infrastructure renting AI infrastructure whether it's power or data center capacity or GPUs”
How the episode opens
Bloomberg Audio Studios, podcasts, radio, news. You're listening to the Bloomberg Intelligence Podcast. Catch us live weekdays at 10 a.m.
Eastern on Apple CarPlay and Android Auto with the Bloomberg Business App. Listen on demand wherever you get your podcasts or watch us live on YouTube. Kimberly Clark buying Ken View in a cash and stock deal worth about $40 billion.
You include debt in there. The enterprise value blows up to 48.7 billion. Diana Gomez is senior equity research analyst for Bloomberg Intelligence and has been covering this deal.
Diana, what's your first take on it? So, it is uh surprising um in in many ways for uh from the perspective of Kimroy Clark. Uh I must confess um it it shows that Ken View really has a lot of work to do to turn around the business uh since it split from J&J um about two years ago.
Um and the third quarter MIS uh just added up to a pile of disappointing results. Diana, I'm looking at the Kimberly Clark stock trading down uh 11 12% here. What's that telling you?
Are they overpaying? Is the market skeptical about synergies? What do you read into that?
I believe more the later in terms of the synergies um it is quite a steep climb. Um um obviously there there's a ton of lowhanging fruit let's say in terms of uh efficiencies that can be gained in terms of plugging the great iconic well-known trusted brands from Canv's um system um that is running at um more efficient level at the moment. Um but it it will uh there is skepticism there because we are talking about revenue synergies as well as cost synergies and this will be quite a complex um new company.
Um at the point when Kimberly Clark was just simplifying as they they were um they are aiming to close the transaction on their international uh business that includes uh segments like tissue um in by mid 2026 um and now this uh merger expected to close around the same time just seems to complicate the the picture a little bit.
From the episode’s captions: roughly the first two minutes, lightly cleaned. Keep watching on YouTube →
Topics
- consumer health m&a
- ai compute deals
- cloud infrastructure spending
- equity earnings
- insurance sector
Companies and tickers mentioned
- KMB
- AMZN
- BRK-B
- Kimberly-Clark
- Kenvue
- Amazon.com
- OpenAI
- Berkshire Hathaway
Watch the episode
Summary, takeaways and quote selection by Octagon. Quotes are short excerpts; the full conversation is in the episode.
More from Bloomberg Intelligence
-
Instant Reaction: Nvidia CEO Jensen Huang Ousted by Nvidia Board | Bloomberg Intelligence -
Nvidia’s Huang Ousted by Board in Move That Roils AI Economy | Bloomberg Intelligence -
CoreWeave Shares Soar After AI Computing Firm Eases Debt Fears | Bloomberg Intelligence -
Anthropic Targets $1.4 Trillion Valuation in Blockbuster IPO | Bloomberg Intelligence -
Nvidia Probe Into CEO Affair Raises Thorny Questions for AI | Bloomberg Intelligence -
Election 'Blue Wave' & Your Wallet; Navigating AI-Driven Market Volatility | Bloomberg Intelligence
Bloomberg Intelligence, this episode and its artwork belong to Bloomberg. Octagon is not affiliated with the show; this page is an independent summary.
